USP comments to FDA on Docket No. FDA-2017-D-5767 for "ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin". Comments were submitted in 2018.
Public Policy
USP comments to FDA on Docket No. FDA-2017-D-5767 for "ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin". Comments were submitted in 2018.